MCRN 005 - The BOSTON Trial
Inspired by the success of the Phase II MCRN 002 STOMP trial, Karyopharm has turned to
MCRN investigators to participate and lead the Phase III global registration trial for selinexor.
Only therapies that are effective, safe and have tolerable side effects can proceed to Phase III testing. Phase III trials compare the "standard of care" to the new treatment and are usually the largest, involving hundreds patients at cancer centres around the world. T
he trial, which will be led
by Dr. Nizar Bahlis of Calgary, will evaluate the combination of selinexor, bortezomib, and dexamethasone (SVd) compared to bortezomib and dexamethasone (Vd).
Kudos to our Canadian team for promoting Canadian research to a global playing field and for bringing the MCRN to an international scale.